Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Huayu is a Traditional Chinese Medicine (TCM) formula, often prepared as granules, primarily utilized for the treatment of liver injury and liver failure, including acute liver failure (ALF) and chronic liver failure (CLF). Its therapeutic efficacy is attributed to its ability to modulate the immune system and inflammatory responses. Specifically, Jiedu Huayu has been shown to inhibit T-cell mediated immunity by reducing the expression of cytotoxic T lymphocyte (CTL) related factors such as perforin, granule B, and PD-1. It also decreases hepatic apoptotic factors like OX62, FAS, and TNFR1, thereby mitigating hepatocyte apoptosis. Furthermore, it influences the balance of various cytokines, increasing anti-inflammatory cytokines like IL-10 and IL-13, while decreasing pro-inflammatory cytokines such as IFN-γ, IL-6, IL-1β, and TNF-α. The drug also regulates the NF-κB signaling pathway and modulates IL-2 and TLR4 expression, contributing to its anti-inflammatory and hepatoprotective effects, and promoting hepatocyte regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Huayu.